BACKGROUND: Maternal diabetes induces neural tube defects, and oxidative stress is a causal factor for maternal diabeteseinduced neural tube defects. The redox gene nuclear factor erythroid 2-related factor 2 is the master regulator of the cellular antioxidant system. OBJECTIVE: In this study, we aimed to determine whether maternal diabetes inhibits nuclear factor erythroid 2-related factor 2 expression and nuclear factor erythroid 2-related factor 2econtrolled antioxidant genes through the redox-sensitive miR-27a. STUDY DESIGN: We used a well-established type 1 diabetic embryopathy mouse model induced by streptozotocin for our in vivo studies. Embryos at embryonic day 8.5 were harvested for analysis of nuclear factor erythroid 2-related factor 2, nuclear factor erythroid 2-related factor 2econtrolled antioxidant genes, and miR-27a expression. To determine if mitigating oxidative stress inhibits the increase of miR-27a and the decrease of nuclear factor erythroid 2-related factor 2 expression, we induced diabetic embryopathy in superoxide dismutase 2 (mitochondrialassociated antioxidant gene)-overexpressing mice. This model exhibits reduced mitochondria reactive oxygen species even in the presence of hyperglycemia. To investigate the causal relationship between miR-27a and nuclear factor erythroid 2-related factor 2 in vitro, we examined C17.2 neural stem cells under normal and high-glucose conditions. RESULTS: We observed that the messenger RNA and protein levels of nuclear factor erythroid 2-related factor 2 were significantly decreased in embryos on embryonic day 8.5 from diabetic dams compared to those from nondiabetic dams. High-glucose also significantly decreased nuclear factor erythroid 2-related factor 2 expression in a dose-and time-dependent manner in cultured neural stem cells. Our data revealed that miR-27a was up-regulated in embryos on embryonic day 8.5 exposed to diabetes, and that high glucose increased miR-27a levels in a dose-and time-dependent manner in cultured neural stem cells. In addition, we found that a miR-27a inhibitor abrogated the inhibitory effect of high glucose on nuclear factor erythroid 2-related factor 2 expression, and a miR-27a mimic suppressed nuclear factor erythroid 2-related factor 2 expression in cultured neural stem cells. Furthermore, our data indicated that the nuclear factor erythroid 2-related factor 2econtrolled antioxidant enzymes glutamate-cysteine ligase catalytic subunit, glutamate-cysteine ligase modifier subunit, and glutathione S-transferase A1 were downregulated by maternal diabetes in embryos on embryonic day 8.5 and high glucose in cultured neural stem cells. Inhibiting miR-27a restored expression of glutamate-cysteine ligase catalytic subunit, glutamatecysteine ligase modifier subunit, and glutathione S-transferase A1. Overexpressing superoxide dismutase 2 reversed the maternal diabeteseinduced increase of miR-27a and suppression of nuclear factor erythroid 2-related factor 2 and nuclear factor erythroid 2-related factor 2econtrolled antioxidant enzymes. CONCLUSION: Our study demonstrates that maternal diabetese induced oxidative stress increases miR-27a, which, in turn, suppresses nuclear factor erythroid 2-related factor 2 and its responsive antioxidant enzymes, resulting in diabetic embryopathy.
Introduction
It has been well established that maternal diabetes increases the risk of neural tube defects (NTDs) in offspring. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The clinical data show that approximate 8000 babies born each year in the United States have birth defects in type 1 or 2 diabetic pregnancies. [11] [12] [13] Data from the National Birth Defects Prevention Study show that the incidence for newborn NTDs are up to 10 times more frequent in women with pregestational diabetes compared to women who never had diabetes or who developed diabetes late in pregnancy (eg, gestational diabetes mellitus). 14 Maternal diabeteseinduced hyperglycemia in the developing embryo has been identified as an adverse factor that impacts embryogenesis and leads to NTD formation. 1, 2, [5] [6] [7] Although evidence from clinical and experimental studies supports the theory that hyperglycemia enhances the generation of reactive oxygen species (ROS) and oxidative stress in developing embryos, 7 ,11 the precise steps by which this occurs are still not fully understood.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a redox sensitive transcription factor and one of the most important cellular defense mechanisms for combating oxidative stress through its ability to regulate phase II detoxifying enzymes and antioxidant proteins. 15, 16 Many endogenous enzymes that catalyze antioxidant reactions are under the control of Nrf2, including heme oxygenase-1, reduced nicotinamide adenine dinucleotide phosphate (NADPH) dehydrogenase (quinone) 1, glutathione (GSH) peroxidase-1, glutamate-cysteine ligase modifier subunit (GLCM), glutamatecysteine ligase catalytic subunit (GCLC), and GSH S-transferase A1 (GSTA1). 17 Inhibiting Nrf2 is associated with a reduction of the antioxidant ability of the Original Research ajog.org cell. 15 Dysregulation of Nrf2 has been involved in many diseases, including alcoholic liver disease, cancer, chronic obstructive pulmonary disease, and neurodegenerative diseases. 15 It has been shown that suppression of Nrf2 activity leads to oxidative stress-induced insulin resistance in adult cardiomyocytes in the diabetic heart. 18 Therefore, we wanted to investigate whether inhibition of Nrf2 by maternal diabetes leads to an abundance of ROS and oxidative stress in the developing embryo.
Regulation of Nrf2 can be divided into Kelch-like ECH (erythroid cell-derived protein with CNC homology)-associated protein 1 (Keap1)-dependent and Keap1-independent mechanisms. 19 In normal conditions, the Nrf2 protein level in the cell is maintained at a low level to prevent constitutive activation of the oxidative stress response by its inhibitor Keap1, which sequesters Nrf2 in the cytosol and facilitates its degradation through the proteasome. 19 Under stressed conditions, the cysteine residues in Keap1 are modified. These modifications lead to a conformational change of Keap1 and result in the release of Nrf2 and disturbed transfer of ubiquitin to Nrf2, ultimately preventing Nrf2 degradation. 19 Despite the above-mentioned regulation of Nrf2 via Keap1, emerging evidence demonstrates that Nrf2 can be regulated independently of Keap1. 19, 20 The emerging evidence shows that some microRNAs (miRNAs) have been shown to be involved in the regulation of Nrf2, including miR-28, -34, -200, and -144. 20 In the present study, we observed that miR-27a can regulate Nrf2 expression at the posttranscriptional level and plays a critical role in diabetic embryopathy. Hyperglycemia-increased miR-27a directly affects Nrf2 messenger RNA (mRNA) stability and results in decreased Nrf2 protein levels, as well as decreased levels of Nrf2-regulated antioxidant genes, including GLCM, GCLC, and GSTA1. Our data reveal a new mechanism by which maternal diabetes induces oxidative stress via the miR-27a-Nrf2 pathway in the developing embryo.
Because oxidative stress is the causal factor for maternal diabeteseinduced NTDs, 7, 11 revealing the role of Nrf2 in diabetic embryopathy will possibly lead to the discovery of new and novel therapeutics for the treatment of this disease. Clinical trials have shown disappointing results in the use of general antioxidants in treating diabetic complications.
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Nrf2 is the master regulator of redox homeostasis, and several Nrf2 activators have displayed their potential to activate the Nrf2 pathway and reduce oxidative stress in diabetic complications. 21, 22 Our study will provide the mechanistic basis for the use of Nrf2 activators as an alternative for the treatment of maternal diabeteseinduced NTDs.
Materials and Methods

Study design
We used the well-established type 1 diabetic embryopathy mouse model induced by streptozotocin for in vivo studies. Embryos at embryonic day (E) 8.5 were harvested for analysis of Nrf2, Nrf2-controlled antioxidant genes, and miR-27a expression. To determine if mitigating oxidative stress inhibits the increase of miR-27a and the decrease of Nrf2 expression by maternal diabetes, we induced diabetic embryopathy in superoxide dismutase 2 (SOD2) (mitochondrial-associated antioxidant gene)-overexpressing mice. This model exhibits reduced mitochondrial ROS in the presence of hyperglycemia. 23 To investigate the relationship between miR-27a and Nrf2 in vitro, we examined C17.2 neural stem cells under normal and high-glucose conditions.
Animals
All procedures for animal use were approved by the Institutional Animal Care and Use Committee of University of Maryland School of Medicine. Wildtype C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). SOD2 transgenic mice, which overexpress human mitochondrial SOD2 under the b-actin promoter, were obtained from Dr Robia Pautler at Baylor College of Medicine. 24 Model of diabetic embryopathy and morphological assessment of NTDs Danvers, MA) at dilutions of 1:1000 in 5% nonfat milk. Membranes were then exposed to goat antirabbit secondary antibodies. To ensure that equivalent amounts of protein were loaded, membranes were stripped and probed with a mouse antibody against b-actin (1:5000; Abcam, Cambridge, United Kingdom). Signals were detected using the SuperSignal West Femto Maximum Sensitivity Substrate kit (Thermo Scientific). Quantification of blots was performed using VisionWorksLS software (UVP Company, Upland, CA). All experiments were repeated in triplicate.
RNA extraction and real-time quantitative polymerase chain reaction
Total RNA was isolated from cells using Trizol reagent (Thermo Scientific) and reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) for mRNA. Reverse transcription of miRNA was performed using a qScript microRNA complementary DNA synthesis kit (Quanta Biosciences, Gaithersburg, MD). Real-time (RT)-quantitative polymerase chain reaction (qPCR) for Nrf2, GCLC, GLCM, GSTA1, b-actin, miR-27a, and small nuclear RNA U6 was performed using the Maxima SYBR green/ROX qPCR master mix assay (Thermo Scientific). The primers for RT-qPCR are listed in the Table. RT-qPCR and subsequent calculations were performed by a StepOnePlus RT PCR system (Applied Biosystems, Foster City, CA).
Statistical analyses
All experiments were repeated in triplicate. Data are presented as means AE SE. Student t test was used for comparisons between 2 groups. One-way or 2-way analysis of variance was performed for >2 group comparisons using the software (SigmaPlot 12.5; Systat Software Inc, San Jose, CA). In analysis of variance, Tukey test was used to estimate significance. Statistical significance was indicated when P < .05.
Results
Maternal diabetes in vivo or high glucose in vitro decreases Nrf2 expression
To investigate the possible role of Nrf2 in diabetic embryopathy, we measured 
Maternal diabetes in vivo or high glucose in vitro increases miR-27a expression
To search for possible miRNAs that may regulate Nrf2 expression, the miRNA target gene prediction tool miRanda (http://www.microrna.org) was used. The prediction showed that miR-27a is a potential regulator of Nrf2 through imperfect complementation with Nrf2 mRNA in the 3' untranslated region (3'UTR) (Figure 2 , A). Next, we examined whether maternal diabetes in vivo or high glucose in vitro affected expression of miR-27a. Maternal diabetes significantly up-regulated expression of miR-27a in the developing embryo (E8.5) (Figure 2 , B). At the same time, high glucose also significantly increased miR27a expression in a dose-and timedependent manner in cultured C17. 
Nrf2 is the target gene of miR-27a
To determine if miR-27a plays a role in the suppression of Nrf2 by maternal diabetes or high glucose, we used a miR27a inhibitor or mimic to manipulate the levels of miR-27a in neural stem cells. High glucose (25 mmol/L) increased miR-27a expression and decreased Nrf2 mRNA levels, whereas transfection of miR-27a inhibitor blocked high glucoseeincreased miR-27a expression The miR-27a-Nrf2 circuit suppresses the expression of Nrf2 responsive genes
Many genes are controlled by Nrf2. 17 In this study, we surveyed these genes and found that 3 genes (GSTA1, GCLC, and GLCM) were inhibited by maternal diabetes in the developing embryo (E8.5) (Figure 4, A) . At the same time, high glucose inhibited GSTA1, GCLC, and GLCM in a dose-dependent manner in C17.2 neural stem cells (Figure 4, B) . Because we demonstrated that miR-27a mediates high glucoseesuppressed Nrf2 expression, we tested whether miR27a mediates high glucoseeinhibited Nrf2-controlled gene expression. Indeed, transfection of miR-27a inhibitor significantly restored high glucosee suppressed GSTA1, GCLC, and GLCM expression in C17.2 neural stem cells (Figure 4, C) . Therefore, our data indicate that miR-27a mediates high glucoseeinhibited Nrf2-controlled gene expression in neural stem cells.
Oxidative stress contributes to the increase of miR-27a and inhibition of Nrf2 expression in diabetic pregnancy
It has been demonstrated that maternal diabetes impairs mitochondrial function by triggering electron leakage and causing ROS production. 8, 23, 34, 35 Theoretically, Nrf2, as a sensor of ROS, should be increased and promote the expression of antioxidant genes under diabetic conditions. However, Nrf2 does not respond to oxidative stress under hyperglycemic conditions. Therefore, we hypothesized that maternal diabetes causes long-term oxidative stress that may inhibit Nrf2 expression according to an epigenetic mechanism. In the present study, we identified miR-27a as an epigenetic factor that affects Nrf2 expression, as well as its downstream genes. Our previous data demonstrated that overexpression of SOD2, a mitochondrial-located antioxidant gene, blocks maternal diabetese induced oxidative stress and significantly reduces the incidence of maternal diabeteseinduced NTD formation from 25-4%. 23 It is possible that elimination of mitochondrial-generated ROS may (Figure 5 , A), as well as restores Nrf2 mRNA expression ( Figure 5 , B) and protein levels ( Figure 5 , C) in the developing embryo (E8.5), indicating that mitochondrialgenerated ROS results in an increase of miR-27a and inhibition of Nrf2. Furthermore, overexpression of SOD2 also restores expression of GSTA1, GCLC, and GLCM in the developing embryo ( Figure 5, D) . Thus, our data indicate that mitochondrial-generated ROS worsens oxidative stress in diabetic embryos through miR-27a-mediated inhibition of Nrf2 expression.
Comment
In this study, we elucidate a mechanism by which maternal diabetes induces oxidative stress in the developing embryo, thereby causing NTDs. We observed that hyperglycemia in vivo and high glucose in vitro increases expression of the epigenetic factor miR-27a. MiR27a inhibits expression of Nrf2, a major cellular defense transcription factor, and suppresses the overall antioxidant capability of cells. Our results reveal a novel pathway that regulates the cellular redox balance in maternal diabeteseinduced embryopathy. We also demonstrated that maternal diabetes inhibits expression of 3 antioxidant enzymes, GSTA1, GCLC, and GLCM, via the miR-27a-Nrf2 pathway to trigger excessive ROS production in the developing embryo. Nrf2 is subject to complex regulatory mechanisms at both the transcriptional and posttranscriptional levels. [15] [16] [17] 19, 20 The Nrf2 promoter contains 2 antioxidant responsive element (ARE)-like sequences that regulate its expression at the transcriptional level, 36 and Nrf2 protein stability is controlled by Keap1, b-transducin repeat containing E3 ubiquitin protein ligase (TrCP), and glycogen synthase kinase 3 (GSK3) at the posttranscriptional level. 17 In addition, new evidence has demonstrated that Nrf2 mRNA is regulated by various miRNAs. 20 In all, 85 miRNAs have been predicted to bind to Nrf2 mRNA to down-regulate its translation. 37 Several miRNAs have been shown to directly bind to the 3'UTR of mRNA, including miR-153, miR-27a, miR-142, and miR-144 in neuronal SH-SY5Y cells 38 ; miR-144 in lymphoblast K562 cells, primary human erythroid progenitor cells, and reticulocytes 39 ; miR-28 in human ; and miR-34a in human embryonic kidney (HEK) 293 cells. 41 In addition to the direct downregulation of Nrf2 by miRNAs, miR200a can target Nrf2 inhibitor Keap1 to affect Nrf2 levels. 42 Here, we reveal that miR-27a in neuroepithelial cells is increased by maternal diabetes, where it then suppresses Nrf2 expression and contributes to the overproduction of ROS and oxidative stress in the developing embryo.
Mitochondrial damage is thought to be the main source of ROS production observed in various diseases. 43 Previous studies have demonstrated that developing embryos exposed to hyperglycemia caused by maternal diabetes exhibit morphological damage to mitochondria and long-term excessive ROS production. 8, 34, 35 We have also shown that repairing mitochondria damaged by high glucose, through overexpression of SOD2, alleviates oxidative stress, indicating that mitochondria are the source of ROS production in diabetic embryopathy. 23 In this study, we found that maternal diabetes inhibits Nrf2, which should be activated in response to oxidative stress induced by hyperglycemia, by increasing the expression of miR27a. We also found that overexpressing SOD2 in diabetic embryos reduces miR-27a expression and restores Nrf2 expression, compared to the diabetic wild-type groups. This means that oxidative stress itself results in inhibition of Nrf2 expression through oxidative stress-sensitive miR-27a. We hypothesize that acute oxidative stress may increase Nrf2 expression, thereby eliminating ROS production, but that the long-term oxidative stress caused by maternal diabetes cannot stimulate Nrf2 expression and enhances ROS production in embryos.
Dysregulation of Nrf2 has been shown to be involved in the etiology of diabetes, such as pancreatic islet beta cell dysfunction 44 and insulin resistance, 18, 44 and its complications, including cardiomyopathy, [44] [45] [46] nephropathy, 44, 45, 47 retinopathy, 48 and atherosclerosis. 49 Emerging evidence suggests that the dysregulation of Nrf2 caused by maternal diabetes impairs embryogenesis and placenta development. It has been demonstrated that gestational diabetes impairs Nrf2-mediated adaptive antioxidant defenses and redox signaling in fetal endothelial cells in utero. 50 Insufficient activation of Nrf2 contributes to maternal diabeteseinduced renal dysmorphogenesis by increasing renal ROS production in the offspring. 51 In addition, Nrf2 signaling is involved in maternal diabeteseinduced defects in the development of the mouse placenta. 52 Prepregnancy maternal diabetes combined with obesity impairs placental mitochondrial function, increases oxidative stress of the placenta High glucoseeincreased miR-27a suppresses nuclear factor erythroid 2-related factor 2 (Nrf2) expression 
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induced by the Nrf2 pathway, and detrimentally alters the metabolism of offspring. 53 Our data further demonstrate that maternal diabeteseinduced oxidative stress results from inhibition of Nrf2 by the epigenetic factor miR-27a in the developing embryo.
Nrf2 regulates the cellular redox balance by controlling expression of antioxidant enzymes. 17 In the present study, we observed that maternal diabetes suppresses 3 Nrf2-controlled genes: GSTA1, GCLC, and GLCM. GCLC and GLCM are used to synthesize cellular antioxidant GSH. 17 GSH is a tripeptide antioxidant that directly scavenges ROS within the cell by donating an electron from 2 molecules of reduced GSH, followed by GSH oxidation to oxidized GSH. 17 It has been reported that hyperglycemia in vivo or high glucose in vitro leads to decreased concentrations of GSH as well as decreased activity of the rate-limiting GSH-synthesizing enzyme g-glutamylcysteine synthetase in the embryonic tissues of diabetic pregnancy or cultured embryos. 54, 55 Our data demonstrate that suppression of GCLC and GLCM by maternal diabetes also contributes to the depletion of GSH in diabetic embryos. GSTA1 is major phase II detoxification enzyme. 17 In addition to this function, GSTA1 has GSH peroxidase activity, which uses GSH to reduce hydrogen peroxide. 17 Previous studies showed that excessive hydrogen peroxide accumulation in diabetic embryos may result from the inhibition of GSTA1. 56 
Clinical significance and study limitations
Experiments in animal models have clearly shown that oxidative stress is responsible for maternal diabetese induced NTDs 1, 7, 11, [56] [57] [58] [59] [60] [61] and congenital heart defects, 62, 63 and clinical research has demonstrated that oxidative stress is involved in various adverse pregnancy outcomes. 64, 65 For example, oxidative stress induced by tobacco smoke is associated with preterm delivery, intrauterine growth restriction, stillbirth, low birthweight, aberrant placental metabolism, syncytial knot formation, and multiple markers of oxidative damage. 66, 67 A case-control study showed that maternal oxidative stress may be an important contributor to preterm birth, regardless of subtype and timing of exposure during pregnancy. 68 Another study has shown that oxidative stress markers are found repeatedly in preeclamptic pregnancies, compared with normotensive pregnancies. 69, 70 Although 2 studies reported Nrf2 dysregulation in deciduas or placentas from preeclamptic patients, 71, 72 it is still unclear whether impaired Nrf2 function contributes to adverse pregnancy outcomes in various maternal conditions. [73] [74] [75] [76] [77] Therefore, further work is needed to determine the potential involvement of the Nrf2 signaling pathway in the induction of adverse pregnancy outcomes.
Based on the importance of Nrf2 in the antioxidant system of the cell, as well as its association with the etiology of diabetic complications, many Nrf2 activators are being developed as therapeutic agents. [44] [45] [46] 78 For example, the Nrf2 activators sulforaphane and cinnamic aldehyde have been shown to significantly attenuate diabetes-associated metabolic disorders and relieve renal damage in mice. 79 Another study has revealed that the Nrf2 inducer MG132 can reduce diabetic kidney disease in mice. 80 A previous study from our FIGURE 4 High glucose inhibits nuclear factor erythroid 2-related factor 2econtrolled gene expression through miR-27a Original Research OBSTETRICS ajog.org laboratory revealed that the Nrf2 activator vinylsulfone reduces high glucoseeinduced NTDs by suppressing cellular stress and apoptosis in cultured mouse embryo. 81 Taken together, these data indicate that Nrf2 could be a therapeutic target for treating maternal diabetes-associated birth defects.
The limitation of this study is that all data were obtained from animal models. Due to the ethics of research, human fetal samples are difficult to obtain for experiments. Translational studies using nonhuman primates may be carried out in the near future. Future studies may assess the therapeutic effect of Nrf2 activators on maternal diabeteseinduced NTDs in rodent and nonhuman primates model. Vinylsulfone, one of the Nrf2 activators that possess the beneficial effect on preventing hyperglycemiainduced NTDs in cultured mouse embryos, 81 could be a good candidate in our future studies.
Conclusions
Our study reveals that maternal diabetes induces oxidative stress in the developing embryo through increasing miR-27a expression and suppressing Nrf2. miR27a inhibits Nrf2 expression, leading to the repression of Nrf2-controlled antioxidant genes GSTA1, GCLC, and GLCM. These data suggest that Nrf2 activators could be therapeutically effective in treating maternal diabetese induced structural birth defects. n Mitochondrial dysfunction contributes to increase of miR-27a and inhibition of nuclear factor erythroid 2-related factor 2 (Nrf2) expression A, miR-27a levels in embryonic day (E)8.5 embryos assessed by real-time (RT)-quantitative polymerase chain reaction (qPCR). B, Nrf2 messenger RNA (mRNA) levels in E8.5 embryos assessed by RT-qPCR. C, Nrf2 and superoxide dismutase 2 (SOD2) protein levels in E8.5 embryos assessed by Western blot. D, mRNA levels of glutathione S-transferase A1 (GSTA1), glutamate-cysteine ligase catalytic subunit (GCLC), and glutamate-cysteine ligase modifier subunit (GLCM) in E8.5 embryos assessed by RT-qPCR. Experiments were repeated using 3 embryos (N ¼ 3) from different dams. Experiments were repeated 3 times. Bar graphs for protein levels show quantitative data from 3 independent experiments. *Significant difference (P < .05) compared with other groups.
DM, diabetic dams; miRNA, microRNA; ND, nondiabetic dams; TG, SOD2 transgenic mice; WT, wild type.
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